were isolated and activated with anti-CD3 and anti-CD28 with or without IL-25 in the presence or absence of TGF-β and analyzed for IL-9 production. Whereas treatment with IL-4 and TGF-β drove T H 9 differentiation, we did not detect IL-9 production after IL-25 stimulation with or without TGF-β, suggesting that IL-25 does not initiate T H 9 polarization in this system ( Fig. 1e) . Because TGF-β together with IL-4 induced the highest expression of IL-17RB, we tested whether IL-25 might enhance the IL-9-inducing effect of TGF-β and IL-4. In naive T cells differentiated under T H 9 conditions, IL-25 treatment led to significantly (P = 0.047) enhanced IL-9 and IL-10 secretion (Fig. 1f) . Consistent with a previous report 8 , we found that, upon IL-25 treatment, IL-5-producing T H 2 cells appear distinct from IL-9secreting T cells as assessed by intracellular cytokine staining ( Fig. 1g ) or IL-9 mRNA expression ( Fig. 1h) . Because GATA3 expression was not affected by IL-25 treatment ( Fig. 1h) , IL-25 seems to regulate IL-9 expression independent of this T H 2-regulating factor. Altogether, our data suggest that IL-17RB is expressed in T H 9 cells and that IL-25 enhances the production of IL-9 in the presence of TGF-β and IL-4.
IL-25-mediated in vivo pathology is abrogated in mice lacking IL-17RA 15 . To test whether IL-17RA expression in T cells is essential for IL-25 function, we isolated naive T cells from wild-type and IL-17RAdeficient mice, activated them as above in the presence of anti-IFN-γ with or without IL-25, and assessed their cytokine profile. We found that IL-17RA deficiency resulted in impaired IL-25-mediated T H 2 differentiation ( Fig. 2a) . Addition of IL-25 to T cells cultured in T H 9-inducing conditions significantly (P = 0.004) enhanced IL-9 secretion in wildtype cells but had no effect on IL-17RA-deficient cells (Fig. 2b) , indicating that IL-17RA is required for the IL-25 effect on IL-9 production.
with the indicated cytokines or antibodies. (b) Real-time RT-PCR of IL-17RB mRNA expression in T cells activated in the presence or absence of IL-4 and/or TGF-β for 2 d. (c) Real-time RT-PCR of IL-17RB mRNA expression at the indicated time points in naive T cells differentiated under T H 1, T H 2, T H 17 and T H 9 conditions. Fold induction was calculated using T H 1 cells as control and normalizing to actin (Actb) expression. (d) Real-time PCR of IL-17RB mRNA expression in naive T cells differentiated under T H 2 and T H 9 condition for 5 d and restimulated with anti-CD3 for 4 h. Naive T cells were used as control. (e) ELISA of IL-9 production in activated naive T cells cultured with or without IL-25 in the presence or absence of TGF-β or in the presence of IL-4 and TGF-β for 4 d, followed by restimulation with anti-CD3. (f-h) ELISA (f), intracellular cytokine staining (g) or real-time PCR, with the control being no treatment (h) of cytokine production in naive T cells stimulated with anti-CD3 and anti-CD28 in the presence of IL-4 and TGF-β with or without IL-25 for 4 d. Data shown are representative of at least two independent experiments.
A r t i c l e s
To determine whether IL-17RB as well is required for the IL-25mediated T H 9 differentiation, we added soluble IL-17RB protein during T H 9 differentiation. The soluble IL-17RB profoundly inhibited IL-25enhanced IL-9 production as well as IL-5 and IL-13 production ( Fig. 2c) . Thus, our data suggest that IL-17 receptors A and B are required for IL-25-mediated regulation of T H 2 and T H 9 cytokine expression.
Enhanced IL-17RB signaling induces IL-9 expression
Although naive T cells express IL-17RB 12 , T H 9 cells express more of it. Because IL-25 regulates IL-9 expression in the presence of TGF-β and IL-4 but not on its own or together with TGF-β, we next tested whether increasing IL-17RB expression in naive T cells could induce IL-9 expression. We thus generated transgenic IL-17RB mice using the CD4 mini-gene 16 (Fig. 3a) . Insertion of a full-length cDNA into this transgenic cassette that contains the CD4 promoter, enhancer and first intron without the silencer results in transgene expression in all T cells. Five founder lines resulted, and four of them were transmitted to progeny. We compared the expression of IL-17RB mRNA in naive CD4 + T cells from four transgenic lines to that in their control littermates ( Fig. 3a) . Lines 1, 3 and 5, expressing more IL-17RB mRNA, were selected for further characterization. Surface expression of IL-17RB protein on CD4 + and CD8 + T cells from CD4-IL-17RB transgenic mice was confirmed by staining with an anti-IL-17RB antibody ( Supplementary Fig. 2) . The CD4-IL-17RB transgenic mice showed normal populations of T and B lymphocytes and monocytes in lymphoid organs (data not shown).
Cytokine expression was analyzed in naive T cells isolated from CD4-IL-17RB transgenic mice or littermate controls activated with anti-CD3 and anti-CD28, with or without IL-25. Consistent with the previous report on the role of IL-25 in promoting T H 2 differentiation 12 , IL-25 treatment induced an increase in the frequency of IL-5-positive cells whereas the frequency of IFN-γ expressing cells was reduced in CD4-IL-17RB transgenic T cells ( Fig. 3b) . Using an enzyme-linked immunosorbent assay (ELISA), we found enhanced production of T H 2 cytokines, including IL-5 and IL-13, and decreased IFN-γ production in cells from two independent transgenic lines compared to wild-type cells ( Fig. 3c) . IL-4 production was decreased, possibly because of the rapid consumption of IL-4 in the culture of IL-17RB transgenic T cells. Indeed, anti-IL-4 receptor (IL-4R)-α treatment resulted in enhanced IL-4 protein expression in the culture supernatants ( Supplementary Fig. 3 ). Consistently with that, we found upregulation of T H 2 cytokine gene expression, as assessed by quantitative RT-PCR ( Fig. 3d) . We could not detect IL-9 expression in IL-25-treated wild-type T cells; however we found a strong induction of IL-9 expression in IL-17RB-transgenic T cells treated with IL-25. Likewise, in wild-type T cells infected with a retrovirus expressing IL-17RB or an empty vector containing IRES-GFP ( Supplementary  Fig. 4 ), IL-25 treatment induced IL-9 secretion only in GFP + , IL-17RB-expressing T cells (Fig. 3e ). In addition, T cells expressing IL-9 were distinct from IL-4-producing T cells. Our results using a transgenic mouse models and retroviral transduction suggest that overexpression of IL-17RB on naive T cells allows IL-25 to induce IL-9-producing T cells. Because IL-17RB and IL-17RA both are critical for IL-25 function, we further examined the signaling mechanisms by which IL-25 regulates IL-9 expression. Isolated naive T cells from wild-type or IL-17RA-deficient mice were retrovirally transduced with IL-17RB or control IRES-GFP and were cultured with IL-25. Cytokine gene expression was examined by real-time RT-PCR in purified GFP + cells restimulated with anti-CD3. Whereas IL-17RB overexpressing T cells upregulated IL-13 and IL-9 expression, this effect was completely absent in IL-17RA-deficient T cells ( Fig. 4a) .
Because IL-25 regulation of IL-9 expression seems to require both IL-17RA and IL-17RB, we next tested the physical interaction between IL-17RA and IL-17RB. When IL-17RA and hemagglutinin (HA)-tagged or wild-type IL-17RB were expressed simultaneously in 293T cells, IL-17RA coimmunoprecipitated with IL-17RB ( Fig. 4b  and Supplementary Fig. 5 ), suggesting the association of IL-17RA and IL-17RB as a signaling complex for IL-25. As IL-25 was initially found to bind to IL-17RB but not IL-17RA 10 , it is not clear whether IL-17RB only mediates ligand recognition or also transduces signals in T cells. IL-17RA binds to the Act1 adaptor protein through the SEFIR (similar expression to fibroblast growth factor genes and IL-17Rs) domain 17 . Although the SEFIR domain in IL-17RB is critical for IL-25-mediated induction of granulocyte colony-stimulating factor in embryonic fibroblast cells 18, 19 , the importance of this domain in T cells is unclear. Overexpression of IL-17RB containing a truncated cytoplasmic domain in activated T cells did not regulate IL-9 or other classical T H 2 cytokine expression upon IL-25 treatment (Fig. 4c) . Altogether, our data suggest that IL-25 signaling through an IL-17RA and IL-17RB complex in T cells regulates T H 2 and T H 9 differentiation.
IL-25-mediated IL-9 production is IL-4 independent
Because overexpression of IL-17RB induced IL-9 expression in the absence of TGF-β and IL-4, we next analyzed whether endogenous expression of TGF-β or IL-4 in CD4-IL-17RB transgenic T cells contributes to IL-9 production. We isolated naive T cells from CD4-IL-17RB transgenic mice or littermate controls, activated them with or without IL-25 in the presence of neutralizing antibodies to TGF-β, IL-4, both TGF-β and IL-4, IL-13, or IL-4Rα. IL-25 treatment induced substantial amounts of IL-9 in CD4-IL-17RB transgenic T cells; TGF-β blockade resulted in a reduction in IL-9 production but no change in IL-5 expression ( Fig. 5a) . There was no further reduction of IL-9 production with the inclusion of other antibodies. In contrast, whereas treatment with antibodies to IL-4 and/or IL-13 or IL-4Rα affected the IL-5 expression, these agents did not significantly reduce IL-9 cytokine expression ( Fig. 5a) .
To confirm the above results, we assessed IL-9 expression in purified naive T cells from IL-4-deficient mice retrovirally transduced with IL-17RB. Upon IL-25 stimulation of these cells, we found a strong reduction of conventional T H 2 cytokine expression in IL-4-deficient versus wild-type T cells, but no change in the abundance of IL-9 mRNA (Fig. 5b) . Thus, our data suggest that IL-25 signaling promotes IL-9 expression through TGF-β-dependent but IL-4-independent mechanisms. Thus, TGF-β not only regulates IL-17RB expression but may also act together with IL-25 signaling to induce IL-9 expression.
IL-9 production in vivo
We next analyzed the in vivo IL-9 production in CD4-IL-17RB transgenic mice using an allergen-induced allergic lung disease model. CD4-IL-17RB transgenic or control littermate mice were repeatedly challenged (4 doses every other day) with the Aspergillus oryzae protease and chicken ovalbumin (OVA) protein allergens intranasally. Mice were put to death 24 h after the last challenge and bronchoalveolar lavage (BAL) fluid cells collected for analysis of inflammatory cell infiltration. CD4-IL-17RB transgenic mice showed A r t i c l e s more cells in the BAL fluid than did wild-type control mice (Fig. 6a) . Lung-infiltrating cells consisted predominantly of eosinophils and CD4 + T cells. Analysis of OVA-specific cytokine production in wildtype and CD4-IL-17RB transgenic splenocytes showed no change in OVA-specific IL-4 production, possibly owing to consumption of IL-4 by T cells in the culture, but showed increased IL-5 and IL-13 production in cells from transgenic mice (Fig. 6b) . Analysis of lung cells and draining lymph node cells taken from allergenchallenged CD4-IL-17RB transgenic or wild-type mice and stimulated with 12-O-tetradecanoylphorbol-13-acetate (PMA) and ionomycin showed similar results (Supplementary Fig. 6 ). In addition, although we could not detect OVA-specific IL-9 expression in allergenchallenged wild-type mice, we consistently observed significant (P = 0.03) OVA-specific IL-9 cytokine production in CD4-IL-17RB transgenic mice compared to challenged wild-type mice (Fig. 6b) .
Although IL-9 is known to be important in allergic inflammation 4, 5, 20 , its role in IL-25-mediated pathology has not been directly analyzed. To further address the role of IL-9 in allergic inflammation in CD4-IL-17RB transgenic mice, we assessed lung inflammation and T H 2 cytokine production in transgenic mice administered a blocking antibody to IL-9 during the induction of allergic lung disease. IL-9 blockade resulted in a significant reduction of total cells and eosinophils in the airway (Fig. 6c) . Moreover, we found a strong reduction of OVA-specific IL-5 and IL-13 production in splenocytes from anti-IL-9 treated CD4-IL-17RB transgenic mice (Fig. 6d) . These data indicate that IL-17RB overexpression upregulates IL-9 and conventional T H 2 cytokines in vivo and that IL-25-mediated IL-9 functions to regulate allergic lung inflammation.
IL-25 deficiency attenuates allergic lung inflammation
We next examined whether IL-25 is required for IL-9 expression in an allergen-induced allergic mouse model. We generated IL-25 mutant mice through gene-targeting in mouse ES cells (Supplementary Fig. 7) . Two loxP sites were introduced into the IL-25 gene locus, flanking exons 2 to 3, and germline IL-25-deficient mice were produced by breeding these 'floxed' mice with CMV-Cre mice. IL-25 mRNA could not be detected by real-time PCR in the lung tissue of IL-25-deficient mice (Supplementary Fig. 8c ). 
A r t i c l e s
We found fewer infiltrating inflammatory cells and classical T H 2 cytokines in the BAL fluid of IL-25-deficient mice after repeated allergen challenge (Supplementary Fig. 8a,b) . Although we could not detect IL-9 protein in the BAL fluids or splenocytes from either wild-type or IL-25-deficient mice, mRNA expression analysis from individual lungs revealed a significant (P = 0.02) reduction in IL-9 mRNA expression in IL-25-deficient mice (Supplementary Fig. 8c ).
IL-9 production was previously reported in the BAL fluid in a different allergic lung disease model 21 . According to this alternate sensitization protocol, IL-25-deficient or wild-type mice were sensitized with OVA in alum at day 0 and 14, followed by intranasal challenge with OVA at day 14, 25, 26 and 27, and inflammatory cell infiltration in the BAL fluid was analyzed 24 h after the last challenge. We found a notable decrease in total cell infiltrates, predominantly composed of eosinophils, in the BAL fluid from IL-25-deficient compared to wild-type mice (Fig. 7a) . As previously described using this model, we could detect IL-19, in addition to conventional T H 2 cytokines, in OVA-specific cells in splenocytes from challenged wild-type mice. However, production of IL-9 and conventional T H 2 cytokines in IL-25-deficient mice was strongly decreased (Fig. 7b) . Analysis of OVA-specific cytokine response in draining lymph node cells ( Fig. 7c) and BAL fluid (Fig. 7d) from IL-25-deficient mice showed no detectable IL-9 and marked reduction of IL-4, IL-5 and IL-13. Consistent with protein expression, we found a significant reduction of IL-9 and T H 2 cytokine mRNA expression in the lungs of IL-25-deficient mice (Fig. 7e) . Thus, our data suggest that IL-25 expression is required for IL-9 expression in allergic lung diseases in vivo.
DISCUSSION
IL-9 was originally described as a T H 2-derived cytokine. IL-4 alone can induce classical T H 2 cytokines but cannot induce IL-9 expression 6 . Indeed, TGF-β was found to be a crucial factor for inducing IL-9, and maximal production could be achieved by adding IL-4. Moreover, recent data have suggested that IL-9-producing T cells are distinct from a conventional T H 2 lineage 7,8 . However, the regulation of these cells remains unclear. Here, we found that IL-17RB is expressed by IL-9-producing T cells and regulates IL-9 production in vitro and in vivo.
IL-17RB is a protein with a single transmembrane domain that binds to IL-25 with high affinity. IL-17RB is expressed by T H 2 but not by T H 1 or T H 17 cells, and IL-25 functions to promote the differentiation of T H 2 cells 12 . In this study, we found that T H 9 cells also express IL-17RB, and IL-25 plays an additional role in promoting T H 9 differentiation. Because IL-25 could not replace IL-4 in inducing T H 9 differentiation, and IL-4 induced IL-17RB expression, it is probable that optimal IL-4-induced IL-17RB expression on T cells is necessary to promote IL-9 production. Indeed, naive T cells from CD4-IL-17RB transgenic mice secreted substantial amounts of IL-9 in response to IL-25 in the absence of IL-4. In contrast, TGF-β seems not only to regulate IL-17RB expression but also to act with IL-25 signaling to induce IL-9 expression. Future studies will be needed to elucidate how downstream signals of the receptors for TGF-β, IL-4 and IL-25 act in inducing and/or enhancing IL-9 expression.
In addition to IL-17RB, IL-17RA is essential for IL-25 function. IL-25-mediated type-2 immune responses require IL-17RA and IL-17RB 15 ; however, whether the expression of both receptors on T cells is required for IL-25 function on T cell differentiation is unclear. Our analysis of T H cell differentiation in vitro indicates that IL-17RA and IL-17RB are essential for IL-25-enhanced T H 2 and T H 9 differentiation in vitro. Thus, constitutive expression of IL-17RA in T cells and inducible expression of IL-17RB may contribute to the determination of T helper lineages. The physical interaction of IL-17RA and IL-17RB indicates that IL-25 functions require the association of the two receptors to form a receptor complex. In addition, the cytoplasmic domain of IL-17RB was required for IL-25 action in enhancing the production of T H 2 cytokines and IL-9, suggesting that IL-17RB not only mediates ligand recognition, it contributes to signal transduction in T cells. Recent studies indicate that the adaptor protein Act1, also known as CIKS (connection to IκB kinase and stress-activated protein kinases) is essential in IL-25-mediated allergic inflammation 18, 19 . It remains unclear whether Act1 is required for IL-25-enhanced T H 2 and T H 9 differentiation. Dissecting the signal transduction pathways involved in IL-25 actions on T cells requires further investigation. Previous work has shown IL-17R-deficient mice show reduced airway inflammation in association with attenuated T H 2 responses in a model of OVAinduced allergic inflammation 22 ; these defects may therefore not be due solely to a defect in IL-17 signaling but also to a defect in IL-25-signaling. TGF-β, IL-2 and IL-4 can regulate IL-9 expression 6,23 . In CD4-IL-17RB transgenic T cells secreting large amounts of IL-9 in response to IL-25, inhibition of IL-4 and IL-2 had little effect on IL-9 expression. However, neutralization of TGF-β abolished the production of IL-9. Furthermore, overexpression of IL-17RB in IL-4-deficient T cells resulted in normal induction of IL-9 expression, although it did not affect IL-5 and IL-13 expression. These data suggest that IL-25 uses different mechanisms to mediate T H 2 differentiation and IL-9 expression. IL-25 may promote T H 2 polarization through an IL-4-dependent pathway, whereas the regulation of IL-9 expression by IL-25 is independent of IL-4 but dependent of TGF-β signaling. Our in vitro data not only identify IL-25 as a IL-9 regulator, but also support the notion that expression of IL-9 and of T H 2 cytokines is regulated by common but also by distinct regulatory mechanisms.
Our in vivo experiments confirm the importance of IL-25 in regulating IL-9 expression. Because IL-25 is an important regulator in allergic asthma 12, 13, 24, 25 and IL-9 is a key player in airway inflammation and asthma 4, 5, 26 , IL-25 may contribute to IL-9-mediated lung inflammation. In mouse model of allergic lung diseases, the enhanced IL-9 expression in IL-17RB transgenic mice and reduced IL-9 expression in IL-25-deficient mice, indicating the importance of IL-25 in the regulation of IL-9. The reduced allergic inflammation in IL-17RB transgenic mice upon inhibition of IL-9 production indicates that IL-25 is one regulator of IL-9 in vivo. Because IL-25 can regulate the production of T H 2 cytokines from non-T, non-B cells and the differentiation of T H 2 and T H 9 cells in allergic diseases, it may serve as an important therapeutic target for treatment of allergy and asthma.
In conclusion, we have provided in vitro and in vivo evidence that IL-25 acts as a regulator of IL-9-producing T cells through the expression of IL-17RB on these cells. Our results indicate an important function of IL-25 in coordinating both conventional T H 2 cytokine and IL-9 expression. Further research on the regulation of T H 9 and T H 2 subsets and their function in immune-mediated diseases will be required to understand the complex effector mechanisms involved in immune responses.
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